Akers Biosciences, Inc. (LON:AKR)‘s stock had its “corporate” rating reiterated by equities research analysts at FinnCap in a research report issued on Tuesday.

Shares of Akers Biosciences (LON:AKR) opened at 185.00 on Tuesday. Akers Biosciences has a 1-year low of GBX 78.75 and a 1-year high of GBX 255.00. The company has a 50 day moving average of GBX 226.04 and a 200 day moving average of GBX 206.80. The firm’s market cap is GBX 10.09 million.

ILLEGAL ACTIVITY WARNING: “Akers Biosciences, Inc. (AKR) Rating Reiterated by FinnCap” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/12/01/akers-biosciences-inc-akr-rating-reiterated-by-finncap.html.

About Akers Biosciences

Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.

Receive News & Stock Ratings for Akers Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc. and related stocks with our FREE daily email newsletter.